BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibition of BCR-ABL with kinase inhibitors such as imatinib mesylate in the treatment of Ph+ CML is the current standard therapy, but it is highly effective in controlling but not curing the disease.